These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 35034512)

  • 1. Telacebec: an investigational antibacterial for the treatment of tuberculosis (TB).
    Lee BS; Pethe K
    Expert Opin Investig Drugs; 2022 Feb; 31(2):139-144. PubMed ID: 35034512
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Telacebec (Q203): Is there a novel effective and safe anti-tuberculosis drug on the horizon?
    Malík I; Čižmárik J; Kováč G; Pecháčová M; Hudecova L
    Ceska Slov Farm; 2021; 70(5):164-171. PubMed ID: 35114793
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Telacebec (Q203): Is there a novel effective and safe anti-tuberculosis drug on the horizon?
    Malík I; Čižmárik J; Kováč G; Pecháčová M; Hudecova L
    Ceska Slov Farm; 2021; 70(5):164–171. PubMed ID: 34875838
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structure of mycobacterial CIII
    Yanofsky DJ; Di Trani JM; Król S; Abdelaziz R; Bueler SA; Imming P; Brzezinski P; Rubinstein JL
    Elife; 2021 Sep; 10():. PubMed ID: 34590581
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The QcrB Inhibitors TB47 and Telacebec Do Not Potentiate the Activity of Clofazimine in Mycobacterium abscessus.
    Sorayah R; Moraski GC; Barkan D; Pethe K
    Antimicrob Agents Chemother; 2021 Nov; 65(12):e0096421. PubMed ID: 34543090
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Delamanid, linezolid, levofloxacin, and pyrazinamide for the treatment of patients with fluoroquinolone-sensitive multidrug-resistant tuberculosis (Treatment Shortening of MDR-TB Using Existing and New Drugs, MDR-END): study protocol for a phase II/III, multicenter, randomized, open-label clinical trial.
    Lee M; Mok J; Kim DK; Shim TS; Koh WJ; Jeon D; Lee T; Lee SH; Kim JS; Park JS; Lee JY; Kim SY; Lee JH; Jo KW; Jhun BW; Kang YA; Ahn JH; Kim CK; Shin S; Song T; Shin SJ; Kim YR; Ahn H; Hahn S; Won HJ; Jang JY; Cho SN; Yim JJ
    Trials; 2019 Jan; 20(1):57. PubMed ID: 30651149
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Delamanid: From discovery to its use for pulmonary multidrug-resistant tuberculosis (MDR-TB).
    Liu Y; Matsumoto M; Ishida H; Ohguro K; Yoshitake M; Gupta R; Geiter L; Hafkin J
    Tuberculosis (Edinb); 2018 Jul; 111():20-30. PubMed ID: 30029909
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthetic investigational new drugs for the treatment of tuberculosis.
    Kwon YS; Koh WJ
    Expert Opin Investig Drugs; 2016; 25(2):183-93. PubMed ID: 26576631
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety, Tolerability, and Pharmacokinetics of Telacebec (Q203), a New Antituberculosis Agent, in Healthy Subjects.
    Kim J; Choi J; Kang H; Ahn J; Hutchings J; van Niekerk C; Park D; Kim J; Jeon Y; Nam K; Shin S; Shin BS
    Antimicrob Agents Chemother; 2022 Jan; 66(1):e0143621. PubMed ID: 34694872
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Deciphering insights into the binding mechanism and plasticity of Telacebec with
    Ray B; Roy KK
    J Biomol Struct Dyn; 2023 Dec; ():1-14. PubMed ID: 38111165
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dual inhibition of the terminal oxidases eradicates antibiotic-tolerant Mycobacterium tuberculosis.
    Lee BS; Hards K; Engelhart CA; Hasenoehrl EJ; Kalia NP; Mackenzie JS; Sviriaeva E; Chong SMS; Manimekalai MSS; Koh VH; Chan J; Xu J; Alonso S; Miller MJ; Steyn AJC; Grüber G; Schnappinger D; Berney M; Cook GM; Moraski GC; Pethe K
    EMBO Mol Med; 2021 Jan; 13(1):e13207. PubMed ID: 33283973
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Potential anti-TB investigational compounds and drugs with repurposing potential in TB therapy: a conspectus.
    Adeniji AA; Knoll KE; Loots DT
    Appl Microbiol Biotechnol; 2020 Jul; 104(13):5633-5662. PubMed ID: 32372202
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bedaquiline: a novel antitubercular agent for the treatment of multidrug-resistant tuberculosis.
    Worley MV; Estrada SJ
    Pharmacotherapy; 2014 Nov; 34(11):1187-97. PubMed ID: 25203970
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Delamanid when other anti-tuberculosis-treatment regimens failed due to resistance or tolerability.
    Kwon YS; Jeong BH; Koh WJ
    Expert Opin Pharmacother; 2015 Feb; 16(2):253-61. PubMed ID: 25327169
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Isolation of Mycobacterium tuberculosis from sputum of tribal, non-tribal pulmonary tuberculosis patients of Andaman & Nicobar islands by conventional culture method and assessment of first line anti-tuberculosis drug susceptibility patterns.
    Mandal A; Parthasarathy G; Burma SP; Sugunan AP; Vijayachari P
    Indian J Tuberc; 2015 Jan; 62(1):23-8. PubMed ID: 25857562
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recent advances in the diagnosis and treatment of multidrug-resistant tuberculosis.
    Ahmad S; Mokaddas E
    Respir Med; 2009 Dec; 103(12):1777-90. PubMed ID: 19660927
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recent updates on drug resistance in Mycobacterium tuberculosis.
    Singh R; Dwivedi SP; Gaharwar US; Meena R; Rajamani P; Prasad T
    J Appl Microbiol; 2020 Jun; 128(6):1547-1567. PubMed ID: 31595643
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Provisional CDC guidelines for the use and safety monitoring of bedaquiline fumarate (Sirturo) for the treatment of multidrug-resistant tuberculosis.
    Centers for Disease Control and Prevention
    MMWR Recomm Rep; 2013 Oct; 62(RR-09):1-12. PubMed ID: 24157696
    [TBL] [Abstract][Full Text] [Related]  

  • 19. QcrB inhibition as a potential approach for the treatment of tuberculosis: A review of recent developments, patents, and future directions.
    Imran M; Abida ; Alotaibi NM; Thabet HK; Alruwaili JA; Asdaq SMB; Eltaib L; Alshehri A; Alsaiari AA; Almehmadi M; Alshammari ABH; Alshammari AM
    J Infect Public Health; 2023 Jun; 16(6):928-937. PubMed ID: 37086552
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Response of
    Chauhan P; van der Meulen SA; Simões Caetano JM; Goojani HG; Botman D; van Spanning R; Lill H; Bald D
    Int J Mol Sci; 2022 Sep; 23(18):. PubMed ID: 36142240
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.